A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors.

@article{Genovese2014API,
  title={A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors.},
  author={Mark C Genovese and Maria Greenwald and C S Cho and Alberto Berman and Ling Jin and Gregory S. Cameron and Olivier B{\'e}nichou and Li Xie and Daniel G. Braun and Pierre-Yves Berclaz and Subhashis Banerjee},
  journal={Arthritis & rheumatology},
  year={2014},
  volume={66 7},
  pages={1693-704}
}
OBJECTIVE To evaluate ixekizumab, an anti-interleukin-17A (anti-IL-17A) monoclonal antibody, in 2 populations of rheumatoid arthritis (RA) patients: biologics-naive patients and patients with an inadequate response to tumor necrosis factor (TNF) inhibitors. METHODS In this phase II, randomized, double-blind study, placebo or ixekizumab was administered subcutaneously to 260 biologics-naive patients and 188 patients with an inadequate response to TNF inhibitors at weeks 0, 1, 2, 4, 6, 8, and… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 48 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 34 references

Validation of rheumatoid arthritis criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845–50

  • AM Van Gestel, CJ Haagsma, PL. van Riel
  • 1998
Highly Influential
5 Excerpts

Similar Papers

Loading similar papers…